Purpose: The aim of this study is to discuss the characteristics, indications, and adverse events (AEs) of sustained-release corticosteroid devices for the treatment of cystoid macular edema (CME). Recent Findings: Ozurdex® is approved for the treatment of diabetic macular edema (DME), retinal vein occlusion-related CME, and noninfectious posterior uveitis (NIPU). It releases dexamethasone over a maximum period of 6 months making repeated intravitreal injections necessary for recurrent CME. Iluvien® releases fluocinolone for up to 36 months and is effective for the treatment of chronic DME. Retisert® (Bausch & Lomb, Rochester, NY, USA) also releases fluocinolone, and is approved for chronic NIPU. Both Iluvien® and Retisert® are non-biodegradable devices and are highly associated with cataract and glaucoma. Summary: Long-acting intraocular corticosteroid formulations offer a more predictable drug-release profile and reduced dosing frequency in comparison to conventional formulations of the same compounds but the risk-benefit ratio must be taken into consideration previous to the implantation of those devices.
- Cystoid macular edema
- Dexamethasone intravitreal implant
- Diabetic macular edema
- Fluocinolone acetonide
- Noninfectious posterior uveitis
- Retinal vein occlusion
ASJC Scopus subject areas